There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cormedix (CRMD – Research Report) and Achieve Life Sciences (ACHV – Research Report) with bullish sentiments.
Cormedix (CRMD)
Needham analyst Serge Belanger maintained a Buy rating on Cormedix today and set a price target of $20.00. The company’s shares closed last Thursday at $2.98, close to its 52-week low of $2.87.
According to TipRanks.com, Belanger is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cormedix with a $22.00 average price target, representing a 623.7% upside. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $19.00 price target.
See the top stocks recommended by analysts >>
Achieve Life Sciences (ACHV)
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. reiterated a Buy rating on Achieve Life Sciences, with a price target of $35.00. The company’s shares closed last Thursday at $6.39, close to its 52-week low of $5.62.
According to TipRanks.com, Higgins is a 2-star analyst with an average return of
Currently, the analyst consensus on Achieve Life Sciences is a Strong Buy with an average price target of $26.67, representing a 323.3% upside. In a report issued on April 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $24.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRMD: